Roche Holding AG (SIX: ROG) and its development partner Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) have reported detailed Phase 3 results showing that investigational sefaxersen achieved a statistically significant 43.1% reduction in proteinuria relative to placebo at Week 37 in adults with primary immunoglobulin A nephropathy. The findings, presented at the American Society of Nephrology Kidney Week 2026 meeting in Denver on October 23, strengthen the clinical evidence supporting an RNA-targeted treatment designed to suppress complement factor B production.
The new disclosure expands on positive interim findings announced in September 2026 by providing the magnitude of the treatment effect and additional information about patient subgroups and hematuria. The IMAgINATION study remains ongoing, with blinded follow-up continuing to assess kidney function over approximately two years. Although the proteinuria result establishes success on the trial’s prespecified primary endpoint, it does not yet demonstrate that sefaxersen prevents kidney failure or slows long-term kidney function decline.
The findings arrive during a period of expanding regulatory activity in IgA nephropathy, with treatments targeting antibody production, complement activation and kidney injury advancing through clinical development or gaining approval. For Roche and Ionis, sefaxersen’s potential differentiation rests on selective inhibition of complement factor B using antisense technology rather than direct antibody-mediated inhibition of circulating complement proteins. Whether this pharmacological approach produces durable clinical benefits will be determined by the remaining IMAgINATION evidence and subsequent regulatory assessment.
What do the latest Phase 3 IMAgINATION results show about sefaxersen’s effect on proteinuria?
IMAgINATION is a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial evaluating sefaxersen in adults with primary IgA nephropathy who remain at high risk of progressive kidney disease despite optimised supportive care. The study enrolled 459 participants, who were randomised equally to receive subcutaneous sefaxersen or placebo for up to 105 weeks. Its prespecified primary efficacy endpoint measures change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 37.
Roche reported that sefaxersen produced a 43.1% reduction in proteinuria relative to placebo, with a 95% confidence interval ranging from 32.5% to 52.0%. The treatment difference was statistically significant, with a p-value below 0.0001. This result supports the conclusion that sefaxersen reduced protein leakage over the interim observation period in the population studied.
The distinction between the reported treatment effect and changes within individual trial groups is important. The 43.1% figure represents the reduction relative to placebo, not necessarily the unadjusted percentage change from baseline among sefaxersen-treated participants. Presenting it as a placebo-adjusted effect preserves the statistical interpretation of the disclosed endpoint.
Roche also reported that treatment effects were consistent across the prespecified patient subgroups evaluated. This suggests that the proteinuria benefit was not confined to a narrowly defined group within the trial population, although detailed subgroup estimates are necessary to assess the precision and consistency of individual comparisons. Subgroup findings are generally supportive rather than separate proof of efficacy in every demographic or clinical category.
The results were obtained in patients already receiving optimised kidney-protective care, making the incremental treatment effect relevant to contemporary IgA nephropathy management. However, the companies have not provided a complete patient-level dataset or comprehensive long-term outcomes in the October announcement. The evidence therefore supports a substantial interim reduction in proteinuria while leaving several clinically consequential questions for continued follow-up.
How does sefaxersen’s antisense mechanism target the alternative complement pathway in IgA nephropathy?
Sefaxersen is a liver-directed antisense oligonucleotide designed to inhibit the production of complement factor B, a protein involved in activation and amplification of the alternative complement pathway. Antisense oligonucleotides work by interacting with specific RNA sequences and reducing production of the corresponding target protein. This approach differs from conventional therapeutic antibodies that bind directly to circulating proteins.
In IgA nephropathy, immune complexes containing abnormal forms of immunoglobulin A accumulate within kidney glomeruli and can trigger inflammatory responses involving the complement system. The alternative complement pathway contributes to amplification of complement activity and has been implicated in the progression of glomerular injury. By reducing factor B production, sefaxersen seeks to interrupt part of this inflammatory process.
Factor B is produced predominantly by the liver and contributes to the formation of the alternative pathway C3 convertase, an enzyme complex that supports complement activation. Lowering circulating factor B can therefore reduce the availability of a protein required for amplification of alternative pathway signalling. The therapeutic hypothesis is that sustained reduction in this activity may decrease complement-associated kidney inflammation and injury.
This mechanism places sefaxersen downstream of the initial formation of abnormal IgA-containing immune complexes. It does not directly correct the underlying production of galactose-deficient immunoglobulin A1 or prevent every biological event associated with the disease. Its potential clinical benefit depends on how much complement-mediated injury contributes to progression within the treated population.
Roche has described sefaxersen as the first RNA-targeted treatment evaluated in IgA nephropathy. Earlier clinical studies reportedly demonstrated reductions in plasma complement factor B and proteinuria, providing a foundation for the Phase 3 programme. The IMAgINATION results now add randomised late-stage evidence that suppression of this pathway can influence an established marker of kidney injury.
Nevertheless, a pharmacologically plausible mechanism does not independently establish long-term renal protection. Complement inhibition may reduce inflammatory activity without completely preventing progression driven by glomerular scarring, vascular factors or other disease processes. Assessing whether factor B suppression produces sustained preservation of kidney function remains essential.
Does the 43.1% proteinuria reduction demonstrate that sefaxersen can prevent kidney failure?
Proteinuria is an important indicator of kidney damage and a recognised predictor of long-term disease progression in IgA nephropathy. Persistent protein leakage is associated with increased risk of declining kidney function, and reductions in proteinuria are widely used to assess treatment activity. The relationship provides a scientific and regulatory basis for evaluating investigational therapies through interim proteinuria endpoints.
The IMAgINATION results show that sefaxersen produced a statistically significant reduction in this marker over 37 weeks. The magnitude of the effect provides evidence of clinical activity and supports further assessment of the treatment’s potential to slow progression. However, proteinuria is a surrogate endpoint, meaning it is used to predict outcomes rather than directly measure every consequence of kidney disease.
The trial’s longer-term objective is to evaluate changes in estimated glomerular filtration rate through Week 105. Estimated glomerular filtration rate provides an assessment of kidney filtering function and is directly relevant to understanding how rapidly chronic kidney disease progresses. A favourable effect on its decline would add evidence that the early proteinuria response translates into sustained protection.
Roche has not yet disclosed the completed Week 105 kidney function results. Consequently, the current findings do not establish a reduction in the need for dialysis or transplantation, nor do they demonstrate that kidney failure can be prevented. Such outcomes require longer observation and appropriate clinical evidence.
Ionis chief executive officer Brett Monia characterised the interim findings as supporting the company’s expectations for sefaxersen as a potential treatment option. Roche chief medical officer Levi Garraway similarly connected the results to the possibility of addressing complement-mediated inflammation and slowing disease progression. Those assessments reflect the companies’ interpretation of the evidence and their expectations for future development, rather than established long-term clinical outcomes.
The ongoing blinded study design is important because it preserves a controlled comparison for subsequent kidney function assessment. Once sufficient follow-up is available, investigators can determine whether the treatment groups differ in the rate of kidney function decline. The magnitude, statistical certainty and clinical relevance of that difference will be central to evaluating sefaxersen’s longer-term therapeutic value.
Why is hematuria resolution an additional consideration in sefaxersen’s Phase 3 findings?
Roche reported that a greater proportion of participants with hematuria at baseline achieved resolution by Week 37 with sefaxersen than with placebo. Hematuria, or blood in urine, can reflect glomerular injury in IgA nephropathy and provides information that is related to but distinct from proteinuria. The finding adds another clinical observation consistent with the treatment’s proposed effects on kidney inflammation.
However, the October company disclosure did not provide the exact proportion of participants achieving hematuria resolution in each treatment group. Without those figures, it is not possible to determine the absolute size of the difference or independently evaluate its statistical precision. Describing the result as a favourable comparison is supported, but assigning an unreported response rate or claiming a specific degree of benefit would not be justified.
The biological rationale for improvement in hematuria is consistent with the proposed mechanism of complement factor B inhibition. If alternative pathway activation contributes to glomerular inflammation, reducing that activity could plausibly influence manifestations associated with tissue injury. Nevertheless, the disclosed findings do not establish a direct causal relationship between factor B suppression and hematuria resolution.
For clinicians, hematuria may provide additional information when evaluating disease activity, but its interpretation depends on the patient’s broader clinical circumstances. A treatment-associated reduction can be informative without necessarily establishing preservation of kidney function or improved long-term outcomes. The clinical significance of the finding will become clearer when more detailed data are available alongside the final kidney function assessment.
What do the reported safety findings indicate about long-term complement factor B inhibition?
The safety assessment is particularly relevant because the complement system contributes to immune defence against infections. Inhibiting components of complement signalling can have consequences for host protection, although the nature and magnitude of those risks depend on the specific therapeutic target and extent of pathway suppression. A medicine intended for prolonged treatment therefore requires careful evaluation of both common and less frequent adverse events.
Roche reported that sefaxersen was generally well tolerated during the disclosed interim period and that its safety profile was consistent with observations from the earlier Phase 2 programme. The company stated that no new safety signals had been identified. These findings are encouraging within the available observation period but should not be interpreted as evidence that complement factor B inhibition is free from clinically important risks.
The October announcement did not provide a full numerical breakdown of overall adverse events, serious adverse events, treatment discontinuations or infection categories. Without those details, the frequency and severity of individual safety outcomes cannot be independently compared in a comprehensive manner. A complete benefit-risk assessment will require the more detailed safety dataset and information on exposure duration.
Long-term treatment may also require consideration of how sustained factor B suppression affects immune responses over time. Depending on the eventual safety findings, regulators may evaluate whether specific monitoring, infection precautions or other risk-management measures are necessary. Such requirements should not be assumed before the appropriate evidence and regulatory decisions are available.
The ongoing trial will provide additional treatment exposure through the Week 105 assessment. Participants may subsequently transition to open-label sefaxersen at the investigator’s discretion, according to the study protocol. This longer observation period could help characterise tolerability and potential delayed adverse effects beyond those apparent during the initial 37 weeks.
The final safety profile will be important in determining how sefaxersen fits alongside other complement-targeted or immune-directed therapies. A favourable interim result is valuable, but chronic kidney disease treatment decisions require confidence that the expected clinical benefit is appropriate for the cumulative treatment burden and safety considerations.
How does sefaxersen differ from approved complement therapies and emerging IgA nephropathy treatments?
The IgA nephropathy treatment landscape has changed rapidly as developers have pursued different points within the disease’s immunological and kidney injury pathways. These approaches include medicines targeting abnormal antibody production, endothelin-mediated kidney damage and complement activation. Sefaxersen enters this environment with a mechanism designed to reduce production of complement factor B through RNA-directed therapy.
A relevant comparison is Novartis’ Fabhalta (iptacopan), an oral complement factor B inhibitor approved in the United States for reducing proteinuria in adults with primary IgA nephropathy at risk of rapid disease progression. Both treatments address factor B, but they do so through different pharmacological approaches. Iptacopan inhibits the activity of factor B directly, while sefaxersen is designed to decrease its production.
The difference may influence pharmacokinetics, dosing requirements, treatment persistence and the speed with which complement activity changes during therapy. However, those potential distinctions cannot be translated into claims of superior efficacy, tolerability or convenience without appropriate comparative evidence. The clinical relevance of the different mechanisms will depend on trial outcomes and real-world treatment characteristics.
The competitive environment also expanded in October 2026 when AstraZeneca announced United States accelerated approval of ULTOMIRIS (ravulizumab) for reducing proteinuria in adults with primary IgA nephropathy at risk of progression. Ravulizumab targets complement component C5, a different point within the complement cascade, and is administered intravenously according to its authorised dosing schedule. The regulatory decision demonstrates that complement-directed therapy has become an established part of the treatment landscape rather than a purely investigational strategy.
Sefaxersen also faces indirect competition from medicines targeting upstream immune activity, including APRIL-directed treatments. These therapeutic approaches seek to influence earlier processes associated with abnormal IgA production, rather than principally addressing downstream complement activation. The growing diversity of mechanisms could eventually support more individualised treatment strategies, although evidence defining optimal sequencing and combinations remains limited.
The 43.1% placebo-adjusted reduction reported for sefaxersen should not be compared directly with isolated efficacy percentages from unrelated trials to establish a therapeutic ranking. Differences in patient populations, background treatment, baseline proteinuria, follow-up periods and statistical methods can materially affect the results. No head-to-head evidence has been presented showing that sefaxersen is superior or inferior to the other named treatments.
Its future differentiation will therefore depend on the full IMAgINATION efficacy and safety package, practical treatment characteristics and evidence of benefits that remain meaningful when patients already have access to established alternatives.
Could once-monthly self-administered sefaxersen improve treatment convenience?
Roche is developing sefaxersen as a once-monthly subcutaneous injection intended to support self-administration at home. This treatment format could provide a practical alternative to therapies requiring more frequent administration or clinic-based infusion. For a chronic disease affecting many patients during working adulthood, the frequency and setting of treatment may influence the overall burden of care.
The intended dosing schedule is supported by the pharmacological characteristics of antisense oligonucleotide therapy, which can produce sustained effects on target protein production after administration. In sefaxersen’s case, the objective is prolonged suppression of factor B sufficient to influence complement pathway activity between monthly doses. Whether the final authorised regimen matches the investigational schedule will depend on regulatory evaluation.
Treatment convenience is not solely determined by injection frequency. Patients may also need training, monitoring and assistance with storage, administration or treatment-related concerns. Specialty pharmacy access and insurance coverage can introduce additional practical considerations, particularly during the early stages of a commercial launch.
For payers and clinicians, the value of home administration will need to be assessed alongside clinical efficacy, long-term safety and cost. A monthly injection may be attractive, but it does not establish superior adherence or patient preference compared with an oral medicine or another less frequently administered treatment. Such outcomes require patient-experience or real-world evidence.
The ability to combine practical administration with sustained kidney protection could eventually become a commercial advantage if supported by the final evidence. At present, the administration format is part of the investigational treatment profile rather than a demonstrated driver of broader clinical adoption.
What does the Roche partnership mean for Ionis Pharmaceuticals’ commercial opportunity?
Sefaxersen originated from Ionis Pharmaceuticals’ antisense technology platform and is being developed through a licensing partnership with Roche. Under the agreement, Roche obtained rights to advance the medicine for complement-mediated diseases, while Ionis retained economic participation through negotiated payments and future commercial arrangements. The structure allows Ionis to participate in the potential value of the asset without independently managing every aspect of its global clinical development.
Ionis has previously received an upfront payment, a licence fee and development milestone payments under the collaboration. The company is also eligible for additional regulatory and sales milestone payments, together with tiered royalties on net sales of sefaxersen. These potential future payments depend on contractual conditions and commercial outcomes and should not be treated as revenue already earned.
The positive Phase 3 result provides support for the potential value of the partnership, although it does not establish the timing or amount of future payments. Roche has not disclosed a definitive regulatory filing date in the October announcement, and no commercial launch has been authorised. The financial implications for Ionis therefore remain contingent on subsequent development and regulatory progress.
The arrangement is also relevant to Ionis’ broader strategy of developing RNA-targeted medicines through a combination of wholly owned programmes and partnered assets. A successful outcome for sefaxersen would provide further clinical validation for the application of antisense technology to a complement-mediated kidney disease. Nevertheless, the drug remains one component of a portfolio that includes other commercial products and development programmes.
For Roche, the programme represents an opportunity to expand its involvement in nephrology through a mechanism distinct from many conventional antibody-based therapies. Its commercial prospects will depend on the final clinical profile and whether the treatment can secure a meaningful position within an increasingly competitive disease category. The partnership’s economic success ultimately requires both regulatory progress and sustained demand following any approval.
What does Ionis Pharmaceuticals’ stock performance suggest about investor sentiment after the Phase 3 disclosure?
Ionis Pharmaceuticals shares closed at $42.93 on October 23, 2026, declining approximately 2.2% during the trading session. The stock remained almost unchanged from its October 16 closing price of $42.94, although trading during the intervening week was volatile. The price movement does not establish a direct negative investor response to sefaxersen’s clinical findings.
The central Phase 3 success had already been announced on September 23, meaning that the October Kidney Week presentation provided additional detail rather than the first indication that the study had met its primary endpoint. Investors may therefore have incorporated expectations of a favourable proteinuria result into the stock before the latest disclosure. The more detailed findings clarify the magnitude of the treatment effect but do not eliminate uncertainty surrounding the longer-term endpoint or regulatory pathway.
The investment significance of sefaxersen also differs between Roche and Ionis. Roche is a diversified pharmaceutical and diagnostics business with numerous commercial and development assets, while Ionis’ economic interest in the drug is structured through a partnership. Future milestone payments and royalties could contribute to Ionis’ revenue if the programme advances successfully, but the magnitude and timing of any benefit remain dependent on contractual triggers and commercial outcomes.
For institutional and biotechnology investors, the key considerations will include the probability of regulatory success, the size of the realistically treatable population, competition from approved therapies and the credibility of long-term kidney protection. The interim data strengthen one important element of that assessment without resolving the full commercial outlook.
What will regulators and nephrologists need from the final IMAgINATION results?
Roche has indicated that it intends to share the interim Phase 3 findings with health authorities, although the October 23 disclosure does not establish a formal regulatory submission date or an accepted marketing application. Discussions with regulators may help determine whether the existing proteinuria evidence supports a potential accelerated approval pathway or whether additional information will be required. Any regulatory outcome remains subject to review by the relevant authority.
The Week 105 kidney function assessment is likely to be particularly influential because it will evaluate whether the early reduction in proteinuria is associated with a slower decline in estimated glomerular filtration rate. This is essential to understanding whether factor B suppression provides sustained clinical protection rather than a temporary improvement in a surrogate marker. The findings will also help clarify the relationship between complement pathway activity and long-term disease progression.
Additional information on hematuria, subgroup responses and treatment safety could further refine the potential clinical role of sefaxersen. In particular, detailed adverse event reporting and longer exposure data will be necessary to evaluate the practical implications of sustained complement inhibition. Such evidence may influence any future monitoring requirements and the balance between efficacy and treatment burden.
The programme’s competitive position will also depend on developments outside the IMAgINATION trial. As other IgA nephropathy treatments accumulate long-term efficacy and safety evidence, expectations for new entrants are likely to evolve. A favourable proteinuria result remains important, but differentiation may increasingly depend on demonstrated kidney function preservation, patient convenience and treatment access.
Sefaxersen’s October 2026 results establish a statistically significant and clinically relevant reduction in proteinuria through an RNA-targeted approach to complement factor B inhibition. The remaining clinical development will determine whether that effect can be sustained and translated into meaningful protection against progressive kidney damage. For Roche and Ionis, the decisive evidence will come from connecting the Week 37 response with the longer-term kidney function and safety outcomes still being assessed in IMAgINATION.
